​

Enveric Biosciences Stock (NASDAQ:ENVB)

ForecastRevenueOwnershipFinancialsChart
Enveric Biosciences by TradingView

Previous Close

$5.05

52W Range

$4.55 - $1.44K

50D Avg

$6.56

200D Avg

$12.53

Market Cap

$3.03M

Avg Vol (3M)

$701.07K

Beta

0.27

Div Yield

-

ENVB Company Profile

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

5

IPO Date

May 04, 2015

Website

ENVB Performance

ENVB Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-9.63M$-16.45M$-27.42M
Net Income$-9.57M$-17.29K$-18.47M
EBITDA$-9.25M$-16.85M$-19.63M
Basic EPS$-19.04$-8.09$-12.77
Diluted EPS$-19.04$-8.09$-12.77

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
SCNIScinai Immunotherapeutics Ltd.
ZVSAZyVersa Therapeutics, Inc.
SPRCSciSparc Ltd.
JSPRJasper Therapeutics, Inc.
ONCOOnconetix, Inc.
SLXNSilexion Therapeutics Ltd.
INDPIndaptus Therapeutics, Inc.
SLRXSalarius Pharmaceuticals, Inc.